BioLargo (BLGO) Stock Price
BioLargo Price
Over the last 18 years BioLargo grew revenue by 28.9% annually, reaching 7.77 M USD. For BioLargo, the net margin of -151.7% is up versus -279.7% a few years ago. The consensus 12-month price target for BioLargo is 0.33 USD, about 243.6% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.
BioLargo stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of BioLargo over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioLargo stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioLargo's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | BioLargo Price |
|---|---|
| 9/2/2026 | 0.09 USD |
| 9/1/2026 | 0.09 USD |
| 8/31/2026 | 0.10 USD |
| 8/28/2026 | 0.10 USD |
| 8/27/2026 | 0.10 USD |
| 8/26/2026 | 0.11 USD |
| 8/25/2026 | 0.11 USD |
| 8/24/2026 | 0.10 USD |
| 8/21/2026 | 0.10 USD |
| 8/20/2026 | 0.08 USD |
| 8/19/2026 | 0.09 USD |
| 8/18/2026 | 0.10 USD |
| 8/17/2026 | 0.10 USD |
| 8/14/2026 | 0.10 USD |
| 8/13/2026 | 0.10 USD |
| 8/12/2026 | 0.10 USD |
| 8/11/2026 | 0.11 USD |
| 8/10/2026 | 0.11 USD |
| 8/7/2026 | 0.11 USD |
| 8/6/2026 | 0.10 USD |
| 8/5/2026 | 0.10 USD |
| 8/4/2026 | 0.11 USD |
| 8/3/2026 | 0.11 USD |
| 7/31/2026 | 0.10 USD |
| 7/30/2026 | 0.11 USD |
| 7/29/2026 | 0.10 USD |
| 7/27/2026 | 0.11 USD |
| 7/23/2026 | 0.12 USD |
| 7/22/2026 | 0.12 USD |
| 7/21/2026 | 0.12 USD |
BioLargo Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLargo Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESk |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | 1.00 | 1.00 | 2.00 | 2.00 | 5.00 | 12.00 | 17.00 | 7.00 | 5.00 | 15.00 |
| – | – | – | – | – | – | – | – | 100.00 | – | 150.00 | 140.00 | 41.67 | -58.82 | -28.57 | 200.00 |
| – | – | – | – | – | – | 300.00 | 300.00 | 50.00 | 50.00 | 40.00 | 50.00 | 41.18 | 42.86 | 42.86 | 42.86 |
| 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 | 1.00 | 2.00 | 6.00 | 7.00 | 3.00 | 2.14 | 6.43 |
| – | – | -3.00 | -4.00 | -4.00 | -5.00 | -6.00 | -6.00 | -7.00 | -6.00 | -5.00 | -4.00 | -4.00 | -14.00 | -3.00 | -10.00 |
| – | – | – | – | – | – | -600.00 | -600.00 | -350.00 | -300.00 | -100.00 | -33.33 | -23.53 | -200.00 | -60.00 | -66.67 |
| – | – | -3.00 | -5.00 | -7.00 | -9.00 | -10.00 | -10.00 | -8.00 | -7.00 | -4.00 | -3.00 | -2.00 | -11.00 | -15.00 | -9.00 |
| – | – | – | 66.67 | 40.00 | 28.57 | 11.11 | – | -20.00 | -12.50 | -42.86 | -25.00 | -33.33 | 450.00 | 36.36 | -40.00 |
| 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 | 130.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BioLargo generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioLargo retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioLargo's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BioLargo has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioLargo's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BioLargo stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLargo Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLargo business model & stock analysis
BioLargo SWOT Analysis
Strengths
BioLargo Inc has several strengths that contribute to its competitiveness and growth potential. These include:
- Strong Intellectual Property (IP) portfolio, providing a competitive advantage in the market.
- Innovative and cutting-edge technologies that address pressing environmental challenges.
- Experienced management team with a proven track record in the industry.
- Strong partnerships and collaborations with government agencies, research institutions, and industry leaders.
- Solid financial position with sufficient resources to support research and development efforts.
Weaknesses
Despite its strengths, BioLargo Inc also faces certain weaknesses that may pose challenges or limitations:
- Dependence on external funding for research and development activities.
- Relatively small market presence compared to some competitors.
- Limited product diversification, focusing primarily on specific environmental solutions.
- Dependency on regulatory approvals and compliance for product commercialization.
- Higher production costs compared to conventional alternatives.
Opportunities
BioLargo Inc can leverage various opportunities to drive its future growth and expansion:
- Increasing global demand for sustainable and eco-friendly solutions, aligning with the company's core offerings.
- Growing governmental initiatives and regulations focused on environmental protection.
- Potential for strategic partnerships and joint ventures to access new markets and increase market share.
- Emerging markets with untapped potential, presenting opportunities for market penetration.
- Advancements in technology and materials that can enhance the efficiency and cost-effectiveness of BioLargo's offerings.
Threats
BioLargo Inc faces certain threats that could hinder its growth and success in the market:
- Intense competition from both established companies and new entrants with similar environmental solutions.
- Economic downturns or market fluctuations that may impact customer spending and demand.
- Unforeseen regulatory changes or delays in obtaining necessary approvals for product commercialization.
- Rapidly evolving technology landscape, requiring continuous innovation and adaptation to maintain a competitive edge.
- Potential environmental liabilities and risks associated with the use and disposal of the company's products.
BioLargo Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLargo Segments
BioLargo Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
BioLargo Revenue by Segment (2/2)
3 Years
5 Years
Max
Details
BioLargo Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
BioLargo historical P/E ratio, EBIT multiple, and P/S ratio
BioLargo annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
BioLargo shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLargo stock splits
Current BioLargo forecasts and price targets in September 2026
Analyst Price Targets 2026BioLargo Earnings Calls
BioLargo Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/12/2026 | -0.01USD | - | 1.33 MUSD | - | 2026 Q2 |
| 5/20/2026 | -0.01USD | - | 816,000.00USD | - | 2026 Q1 |
| 11/14/2025 | -0.01USD | - | 2.90 MUSD | - | 2025 Q3 |
| 8/12/2025 | -0.01USD | - | 3.57 MUSD | - | 2025 Q2 |
| 11/14/2024 | -USD | - | 5.20 MUSD | - | 2024 Q3 |
| 5/16/2024 | -USD | - | 3.42 MUSD | - | 2024 Q1 |
| 4/1/2024 | -USD | - | 2.78 MUSD | - | 2023 Q4 |
| 11/13/2023 | -USD | - | 4.79 BUSD | - | 2023 Q3 |
BioLargo shareholder structure
| % | Name |
|---|---|
8.36648% | |
3.41094% | |
0.03839% |
BioLargo Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
6.80% | SEC ↗ |
BioLargo Executives and Management Board
8 members · avg. age 61 · 25 % women
Mr. Dennis Calvert (62)
Chairman of the Board, President, Chief Executive Officer · since 2002
317,952.00 USD
Management
Mr. Kenneth Code (78)
Chief Scientific Officer, Director · since 2007
Mr. Joseph Provenzano (56)
Executive Vice President - Operations, Corporate Secretary, Director · since 2002
Mr. Charles Dargan (70)
Chief Financial Officer
Board of Directors
Mr. Dennis Marshall (82)
Independent Director
Ms. Christina Bray (37)
Independent Director
Ms. Linda Park (47)
Independent Director
Mr. Jack Strommen (55)
Independent Director
Frequently asked questions about BioLargo
BioLargo Inc is a diversified environmental company focused on developing innovative technologies to address various global challenges. The business model of BioLargo Inc revolves around commercializing and licensing its proprietary technologies in areas such as water and air treatment, advanced wound care, and animal health. The company combines research, development, and commercialization to bring sustainable solutions to market. BioLargo Inc aims to create value for its shareholders by developing and marketing cost-effective and efficient products that provide significant benefits to industries and communities alike.
BioLargo Inc is primarily active in the fields of water treatment, environmental sustainability, and industrial solutions.
The main competitors of BioLargo Inc in the market are [competitor 1], [competitor 2], and [competitor 3]. These companies have established a strong presence in the [relevant industry] sector, competing with BioLargo Inc on various fronts. However, BioLargo Inc has continuously demonstrated its unique competitive advantage through its innovative [products/services] and commitment to [industry-specific goals]. With its extensive expertise and strategic initiatives, BioLargo Inc remains a formidable player in the market, consistently striving for growth and market leadership.
BioLargo Inc is a globally recognized company specializing in innovative water and environmental technologies. Established in 1989, BioLargo has dedicated years of research and development to create cutting-edge products aimed at solving some of the world's biggest challenges, including clean water availability and air quality. The company is renowned for its proprietary technology called Advanced Oxidation System (AOS), which effectively eliminates contaminants in water with high efficiency. With a strong commitment to sustainability and environmental responsibility, BioLargo continues to revolutionize industries such as water treatment, oil and gas, food processing, and more. The company's relentless pursuit of excellence positions BioLargo as a leader in providing transformative solutions for a healthier planet.
BioLargo Inc has achieved significant milestones throughout its history. It has developed innovative and sustainable technologies for various industries. Some notable achievements include the commercialization of its highly effective odor control products, such as CupriDyne Clean, which addresses odor issues across multiple sectors. The company has also successfully developed and patented its AOS water treatment system, which offers cost-effective and efficient solutions for contaminated water treatment. Furthermore, BioLargo has formed strategic partnerships and collaborations with leading organizations, enhancing its market reach and potential. These milestones demonstrate BioLargo Inc's commitment to finding innovative solutions for environmental challenges and establishing itself as a leader in its industry.
BioLargo Inc primarily operates in the United States. As a leading environmental engineering company, BioLargo provides innovative solutions for air and water pollution control, odor and moisture management, and sustainable energy technologies. The company's headquarters is located in California, with operations and partnerships across different states in the U.S. BioLargo Inc is focused on delivering cost-effective, scalable, and eco-friendly solutions to address major environmental challenges.
BioLargo Inc represents a commitment to innovation, sustainability, and environmental responsibility. The company's corporate philosophy is centered around providing cutting-edge solutions for water and air quality challenges. BioLargo believes in developing and commercializing advanced technologies that address crucial global issues, such as pollution, water scarcity, and climate change. With a focus on research and development, BioLargo strives to create sustainable and cost-effective products that improve the quality of life for people and the planet. As a leader in environmental solutions, BioLargo Inc continues to demonstrate its dedication to making a positive impact on the world through its values and corporate philosophy.
Analysts currently set an average price target of 0.33 USD for the BioLargo stock (median: 0.33 USD), implying +243.6 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the BioLargo stock: 6 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the BioLargo share trades at 0.08 EUR (0.09 USD).
BioLargo Inc is an innovative company specializing in the development and marketing of environmentally friendly technologies. The company's business model is designed to create a sustainable future by providing solutions to some of the world's most urgent environmental problems. The company operates in three business segments: BioLargo Water, BioLargo Engineering, and BioLargo Sciences. Each division offers specialized technologies and products tailored to customer needs. BioLargo Water specializes in water treatment and desalination. The company has developed an award-winning technology called AOS, which is one of the most effective in the market. AOS stands for Advanced Oxidation System and uses a unique combination of ozone and ultraviolet light to achieve high water quality. The company also offers products such as water filters and desalination systems. BioLargo Engineering focuses on solving environmental engineering problems. It provides specialized engineering services and technical consulting to customers experiencing issues in their facilities. The company has developed a unique method to disinfect air streams without the release of harmful chemicals. The technology is called CupriDyne Clean and aims to control odors and VOCs in the air. BioLargo Sciences specializes in the development of technologies for the medical and healthcare industries. The company specializes in combating infectious diseases and biological threats. It has developed a patented technology called Clyraguard, which provides long-lasting disinfection. The company also offers products such as hand sanitizers and mouth rinses. BioLargo Inc is an environmentally-focused company that has developed multiple patented technologies in the fields of environmental engineering, health, and medicine. The company strives to offer customers effective and environmentally friendly solutions, making the planet a better place. The company has a track record of success stories, such as successfully implementing the AOS technology in a Canadian gold mine to clean wastewater. It has also improved the process of air disinfection in poultry farms, leading to improved quality of life for the animals. BioLargo Inc has an experienced leadership team composed of experts from various fields, including engineers, scientists, entrepreneurs, and environmentalists. The management team has a strong vision for the future and is working hard to achieve their goals. Overall, BioLargo Inc offers a wide range of environmentally friendly technologies and products. The company aims to provide customers with effective and safe solutions to solve some of the world's most urgent environmental problems.
The expected revenue of BioLargo is 5.23 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioLargo is -15.35 M USD. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for BioLargo at the moment.
The P/S cannot be calculated for BioLargo currently.
The Eulerpool Quality Score for BioLargo is 4/10.
The ISIN of BioLargo is US09065A1007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioLargo is A0MLEC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioLargo is BLGO. The ticker symbol is used to trade BioLargo shares on the stock exchange.
BioLargo paid dividends every year for the past 0 years.
BioLargo is assigned to the 'Commodities' sector.
The dividends of BioLargo are distributed in USD.
BioLargo stock
BioLargo Peer Group
BioLargo Ticker
BioLargo FIGI
All fundamentals and in-depth analysis of BioLargo
Our stock analysis for BioLargo stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioLargo. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.